Edward v loftus jr (4 risultati)

Buch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -By the time this issue of Gastroenterology Clinics of North America is released, it will have been 16 years since infliximab was approved by the US Food and Drug Administration for the treatment of moderate to severe Crohn disease. Not only have we come a long way in understanding the efficacy and safety of infliximab, we are beginning to understand how and when to use the drug. Furthermore, as of this writing, we have five other biologic agents approved for either Crohn disease or ulcerative colitis, and there are many more molecules currently in drug development for these indications. In this issue,the Editors have assembled a collection of experts to provide the most cutting-edge information on the status of biologic therapy for inflammatory bowel disease. Englisch.…

Buch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Dr. Loftus is a widely recognized expert in the diagnosis and treatment of Crohn's disease. He has created an issue devoted the current state-of-the-art on Crohn's disease; authors have written comprehensive reviews on the latest research to inform clinical diagnosis and treatment. Articles are devoted to the following topics: Genetics; Epidemiology, natural history, and risk stratification of Crohn's disease; The microbiome in Crohn's disease: Role in pathogenesis and role of microbiome replacement therapies; Endoscopic and radiographic assessment of Crohn's disease; Intestinal and non-intestinal cancer risk in Crohn's disease; Sexuality, fertility, and pregnancy in Crohn's disease; Interdisciplinary management of perianal Crohn's disease; Targeting specific immunologic pathways in human inflammatory bowel disease; Evolution of treatment paradigms in Crohn's disease; Preventing and managing postoperative recurrence of Crohn's disease; Where and how to use anti-TNF agents and anti-integrins in Crohn's disease; Ustekinumab and anti-interleukin-23 agents in Crohn's disease; Update on therapeutic drug monitoring in Crohn's disease; and Janus kinase antagonists and other novel small molecules for the treatment of Crohn's disease. Readers will come away from this issue armed with the information they need to improve management of this disease as well as patient outcomes. Englisch.…

Buch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - By the time this issue of Gastroenterology Clinics of North America is released, it will have been 16 years since infliximab was approved by the US Food and Drug Administration for the treatment of moderate to severe Crohn disease. Not only have we come a long way in understanding the efficacy and safety of infliximab, we are beginning to understand how and when to use the drug. Furthermore, as of this writing, we have five other biologic agents approved for either Crohn disease or ulcerative colitis, and there are many more molecules currently in drug development for these indications. In this issue,the Editors have assembled a collection of experts to provide the most cutting-edge information on the status of biologic therapy for inflammatory bowel disease.…

Buch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Dr. Loftus is a widely recognized expert in the diagnosis and treatment of Crohn's disease. He has created an issue devoted the current state-of-the-art on Crohn's disease; authors have written comprehensive reviews on the latest research to inform clinical diagnosis and treatment. Articles are devoted to the following topics: Genetics; Epidemiology, natural history, and risk stratification of Crohn's disease; The microbiome in Crohn's disease: Role in pathogenesis and role of microbiome replacement therapies; Endoscopic and radiographic assessment of Crohn's disease; Intestinal and non-intestinal cancer risk in Crohn's disease; Sexuality, fertility, and pregnancy in Crohn's disease; Interdisciplinary management of perianal Crohn's disease; Targeting specific immunologic pathways in human inflammatory bowel disease; Evolution of treatment paradigms in Crohn's disease; Preventing and managing postoperative recurrence of Crohn's disease; Where and how to use anti-TNF agents and anti-integrins in Crohn's disease; Ustekinumab and anti-interleukin-23 agents in Crohn's disease; Update on therapeutic drug monitoring in Crohn's disease; and Janus kinase antagonists and other novel small molecules for the treatment of Crohn's disease. Readers will come away from this issue armed with the information they need to improve management of this disease as well as patient outcomes.…